Results 251 to 260 of about 150,466 (311)

Semaglutide normalizes increased cardiomyocyte calcium transients in a rat model of high fat diet‐induced obesity

ESC Heart Failure, Volume 12, Issue 2, Page 1386-1397, April 2025.
Sequeira et al. reveal how the glucagon‐like peptide‐1 receptor agonist (GLP‐1‐RA) semaglutide restores cardiomyocyte function in rats subjected to a high‐fat/high‐fructose diet (HFD). Employing fluorescence‐ and patch‐clamp technology in isolated cardiac myocytes, they demonstrate that semaglutide reverses HFD‐induced activation of L‐type calcium ...
Vasco Sequeira, Julia Theisen, Katharina J. Ermer, Marie Oertel, Anton Xu, David Weissman, Katharina Ecker, Jan Dudek, Martin Fassnacht, Alexander Nickel, Michael Kohlhaas, Christoph Maack, Ulrich Dischinger   +12 more
wiley   +1 more source

FDG PET/CT imaging and circulating biomarkers of inflammation in desmoplakin cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1485-1489, April 2025.
Abstract Aims Inflammation has been implicated in the pathogenesis of desmoplakin (DSP) cardiomyopathy, and retrospective studies have described abnormal myocardial fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) findings in symptomatic patients eventually diagnosed with DSP cardiomyopathy.
Sanjay Divakaran, Vinay Randhawa, Usman A. Tahir, Matthew Robertson, Anam A. Waheed, Anna Perillo, Leanne Barrett, Ron Blankstein, Mark W. Feinberg, Marcelo F. Di Carli, Neal K. Lakdawala   +10 more
wiley   +1 more source

CardiLect: A combined cross‐species lectin histochemistry protocol for the automated analysis of cardiac remodelling

ESC Heart Failure, Volume 12, Issue 2, Page 1398-1415, April 2025.
Abstract Background Cardiac remodelling, a crucial aspect of heart failure, is commonly investigated in preclinical models by quantifying cardiomyocyte cross‐sectional area (CSA) and microvascular density (MVD) via histological methods, such as immunohistochemistry.
Tamás G. Gergely, Tamás Kovács, Andrea Kovács, Viktória E. Tóth, Nabil V. Sayour, Gábor M. Mórotz, Csenger Kovácsházi, Gábor B. Brenner, Zsófia Onódi, Balázs Enyedi, Domokos Máthé, Przemyslaw Leszek, Zoltán Giricz, Péter Ferdinandy, Zoltán V. Varga   +14 more
wiley   +1 more source

SPARCL1 and NT‐proBNP as biomarkers of right ventricular‐to‐pulmonary artery uncoupling in pulmonary hypertension

ESC Heart Failure, Volume 12, Issue 2, Page 1416-1426, April 2025.
Abstract Aims SPARCL1 was recently identified as a biomarker of right ventricular (RV) maladaptation in patients with pulmonary hypertension (PH), and N‐terminal pro‐brain natriuretic protein (NT‐proBNP) is an established biomarker of RV failure in PH. The present study investigated whether NT‐proBNP and SPARCL1 concentrations are associated with load ...
Oliver Dörr, Stanislav Keranov, Paulina van Wickern, Holger Nef, Christian Hamm, Pascal Bauer, Christian Troidl, Samuel Sossalla, Sandra Voss, Christoph Liebetrau, Manuel J. Richter, Henning Gall, Werner Seeger, Ardeschir Ghofrani, Athiththan Yogeswaran, Khodr Tello   +15 more
wiley   +1 more source

Mortality risk stratification for Takotsubo syndrome: Evaluating CRP measurement alongside the InterTAK prognostic score

ESC Heart Failure, Volume 12, Issue 2, Page 1427-1436, April 2025.
Abstract Background and objectives Initially described as a benign acute cardiomyopathy, Takotsubo syndrome has been linked to elevated mortality rates. Emerging evidence suggests that unresolved myocardial inflammation may contribute to this adverse prognosis.
Loïc Faucher, Kensuke Matsushita, Shinnosuke Kikuchi, Taraneh Tatarcheh, Benjamin Marchandot, Amandine Granier, Said Amissi, Antonin Trimaille, Laurence Jesel, Patrick Ohlmann, Kiyoshi Hibi, Valérie Schini‐Kerth, Olivier Morel   +12 more
wiley   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

The use of echocardiography and echocardiographic findings in patients hospitalized for acute heart failure

ESC Heart Failure, EarlyView.
Abstract Aims Transthoracic echocardiography (TTE) is recommended as a key investigation in patients with acute heart failure (AHF) in major guidelines. However, utilization and benefits are yet to be known in Thai patients. The study aims to evaluate the benefits of TTE and identify factors associated with the decision to perform TTE on patients with ...
Koravich Lorlowhakarn, Thanaporn Ratchataswan, Thiratest Leesutipornchai, Aunchalee Jaroenlapnopparat, Palapun Waitayangkoon, Supanee Sinphurmsukskul, Sarawut Siwamogsatham, Sarinya Puwanant, Smonporn Boonyaratavej Songmuang, Aekarach Ariyachaipanich   +9 more
wiley   +1 more source

Prognostic utility of advanced lung cancer inflammation index in heart failure with preserved ejection fraction

ESC Heart Failure, EarlyView.
The advanced lung cancer inflammation index (ALI) is an integrated marker of inflammation and nutritional status, calculated by body mass index × serum albumin / neutrophil‐to‐lymphocyte ratio. Low ALI levels were significantly associated with poor prognosis in elderly multimorbid HFpEF patients.
Daisuke Sakamoto, Yuki Matsuoka, Masahiro Seo, Takahisa Yamada, Daisaku Nakatani, Katsuki Okada, Akihiro Sunaga, Hirota Kida, Taiki Sato, Tetsuhisa Kitamura, Shunsuke Tamaki, Masamichi Yano, Takaharu Hayashi, Akito Nakagawa, Yusuke Nakagawa, Yoshio Yasumura, Shungo Hikoso, Yohei Sotomi, Yasushi Sakata, on behalf of the OCVC‐Heart Failure Investigators   +19 more
wiley   +1 more source

Improvements in medical therapy and prognosis for patients with HFrEF following the 2021 ESC HF guidelines

ESC Heart Failure, EarlyView.
Abstract Aims The guideline‐directed medical therapy (GDMT) sequencing strategy for patients with heart failure (HF) and reduced ejection fraction (HFrEF) underwent a paradigm shift with the 2021 ESC HF guidelines, from stepwise escalation to rapid simultaneous initiation of quadruple therapy.
Kristian Berge, Henrik Schirmer, Tarjei Øvrebotten, Hamza Nahoui, Lars Gullestad, Charlotte Björk Ingul, Torstein Hole, Rune Mo, Kristina Larsby, Tone M. Norekvål, Torbjørn Omland, Stein Ørn, Peder L. Myhre   +12 more
wiley   +1 more source

Interconnected pathways and emerging therapies in chronic kidney disease and heart failure: A comprehensive review

ESC Heart Failure, EarlyView.
Abstract Chronic kidney disease (CKD) and chronic heart failure (HF) frequently coexist and, when comorbid, are associated with poorer outcomes. These two diseases have common risk factors, such as diabetes, obesity and hypertension, and common pathophysiological connected mechanisms, including inflammation, endothelial dysfunction, neurohormonal ...
Johann Bauersachs, Eri Toda Kato, Janani Rangaswami   +2 more
wiley   +1 more source